SBIR/STTR Research Award
SCAR TISSUE INHIBITION AROUND SOFT TISSUE IMPLANTS
Award amount
$476,362Program and phase
SBIR · Phase IIAward year
1989Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- WHALEN BIOMEDICAL, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
THE OBJECTIVE OF THIS PROGRAM IS THE DEVELOPMENT OF AN IMPROVED MAMMARY PROSTHESIS SIGNIFICANTLY LESS PRONE TO THE MAJOR COMPLICATION OF CURRENT DEVICES: THE FORMATION OF A THICKENED FIBROUS TISSUE CAPSULE AROUND THE IMPLANT. THE BASIC APPROACH IS TO ALTER THE SURFACE MORPHOLOGY OF THE IMPLANT FROM SMOOTH SILICONE RUBBER TO A TEXTURED SURFACE, WHICH PROMOTES TISSUE ADHESION AND ATTACHMENT. THIS SURFACEWILL BE GENERATED BY EXTRUDING SILICONE RUBBER FIBRILS AND FORMING THEM INTO A MATRIX BONDED TO THE EXTERIOR OF THE IMPLANT. BASED ON EXPERIENCE WITH IMPLANTABLE COMPLIANCE CHAMBERS FOR ARTIFICIAL HEART SYSTEMS, SURFACE MORPHOLOGY WAS SHOWN TO BE A MAJOR DETERMINANT OF TISSUE CAPSULE THICK-NESS FORMED AROUND THOSE DEVICES. TEST SPECIMENS OF SMOOTH SILICONE RUBBER, A TEXTURED SURFACE PREVIOUSLY CHARACTER- IZED, AND THE TEXTURED SILICONE RUBBER WILL BE EVALUATED IN VIVO FOR TISSUE CAPSULE THICKNESS AND COMPOSITION HISTOLOGY.OTHER USES FOR THE TECHNOLOGY DEVELOPED INCLUDE IMPROVED COMPLIANCE CHAMBER SYSTEMS, CARDIAC PACEMAKER CASINGS, IMPLANTABLE POLYMERIC DRUG DELIVERY SYSTEMS, OR ANY APPLICA-TION IN WHICH EXCESSIVE SCAR TISSUE FORMATION CAN CAUSE UNDESIRABLE SYMPTOMS OR INTERFERE WITH THE PERFORMANCE OF THE DEVICE.
Technology keywords
Not reported